Biopharmaceuticals Breakthroughs and Beyond: Understanding and Mitigating Adverse Drug Reactions (ADRs)
Abstract
Biopharmaceuticals, while revolutionizing medicine, harbor potential for adverse reactions (ADRs)1,2,3. This presentation seeks to offer an exploration of adverse reactions (ADRs) linked to biopharmaceuticals. It will address the current scenario, emerging challenges, and essential pharmacovigilance strategies to enhance the safety of biopharmaceutical therapy.
Material :
This article is based on a comprehensive review of scientific literature published between 2017 and 2024. Relevant articles were identified in PubMed and Google Scholar using the keywords "biopharmaceuticals," "adverse reactions," "pharmacovigilance," and related terms. In addition to research papers, we reviewed case studies and reports from the World Health Organization (WHO) and the US Food and Drug Administration (FDA).
Methods :
This is a narrative review aimed at providing a comprehensive overview of the current understanding of ADRs associated with biopharmaceuticals. We critically assessed the identified literature, analyzed trends and patterns in ADR reporting, and incorporated case studies to illustrate the challenges and complexities involved.
References
Reijers JAA, Malone KE, Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals. Br J Clin Pharmacol. 2019 Jul;85(7):1418-1426.
2.
J. Cavagnaro, Considerations for the Preclinical Safety Evaluation of Biopharmaceuticals Reference Module in Biomedical Sciences, Elsevier, 2015, ISBN 9780128012383,
3.
Batista-Duharte Alexander, Aliño Salvador F. Immune-related adverse Events (irAEs) of biopharmaceuticals, Frontiers in Allergy
4.
Favour Danladi Makurvet,Biologics vs. small molecules: Drug costs and patient access,Medicine in Drug Discovery,Volume 9,2021,1000
5. Kesik-Brodacka M. Progress in biopharmaceutical development. Biotechnol Appl Biochem. 2018 May;65(3):306-322.
6. Polson AG, Fuji RN. The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients. Br J Pharmacol. 2012 Jul;166(5):1600-2.
7. Vermeer NS, Giezen TJ, Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice. Clin Pharmacol Ther. 2019 Apr;105(4):962-969.
8. Kissner T, Blaich G, Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting. MAbs. 2021 Jan-Dec;13(1):1938796.
9.
Serena Dasani, Rohan Palanki, Chapter 85 - Biopharmaceuticals, In Handbook for Designing and Conducting Clinical and Translational Research, Translational Surgery, Academic Press, 2023, Pages 535-538,
10. Machado-Alba JE, Jiménez-Morales AL. Adverse drug reactions associated with the use of biological agents. PLoS One. 2020 Dec 18;15(12):e0240276.
11. Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. Int J Health Policy Manag. 2015 Mar 9;4(5):295-305. doi: 10.15171/ijhpm.2015.55. PMID: 25905480; PMCID: PMC4417633.
12. Machado-Alba JE, Jiménez-Morales AL, Moran-Yela YC, Parrado-Fajardo IY, Valladales Restrepo LF. Adverse drug reactions associated with the use of biological agents. PLoS One. 2020 Dec 18;15(12):e0240276. doi: 10.1371/journal.pone.0240276. PMID: 33338057; PMCID: PMC7748267.
13.
Machado-Alba, Jorge & Jiménez-Morales, Anyi & Moran-Yela, Yulieth & Parrado-Fajardo, Ilsa & Valladales-Restrepo, Luis. (2020). Adverse drug reactions associated with the use of biological agents. 10.1101/2020.09.24.311241.
